Theratechnologies Reports on its Annual Meeting of Shareholders

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Theratechnologies (NASDAQ: THTX) held its annual virtual shareholders meeting on May 29, 2025. During the meeting, shareholders elected eight directors to the Company's Board for a one-year term. All proposed candidates were successfully elected with approval rates ranging from 77.98% to 84.03%. Joseph Arena received the highest shareholder support with 84.03% votes in favor, while Dawn Svoronos received 77.98% of favorable votes.

Additionally, shareholders appointed KPMG LLP as the Company's auditors for the current fiscal year and approved an omnibus long-term incentive plan benefiting directors, executive officers, and employees of the Company and its subsidiaries.

News Market Reaction – THTX

+0.39%

1 alert

+0.39% News Effect

On the day this news was published, THTX gained 0.39%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

05/29/2025 - 02:00 PM

MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.

Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term, appointed KPMG LLP as the Company’s auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan for the benefits of the directors, executive officers and employees of the Company and those of its subsidiaries.

All candidates proposed for the position of director were elected in the following proportion:

	FOR	% FOR	ABSTENTION	% ABSTENTION
Joseph Arena	20,473,944	84.03%	3,890,222	15.97%
Frank Holler	19,089,786	78.35%	5,274,380	21.65%
Paul Lévesque	19,027,772	78.10%	5,336,394	21.90%
Andrew Molson	19,066,145	78.25%	5,298,021	21.75%
Dawn Svoronos	18,998,230	77.98%	5,365,936	22.02%
Elina Tea	19,163,502	78.65%	5,200,664	21.35%
Dale Weil	19,005,768	78.01%	5,358,398	21.99%
Jordan Zwick	19,618,725	80.52%	4,745,441	19.48%

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter).

Contacts:

Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
pdubuc@theratech.com
438-315-6608

Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
514-336-7800

FAQ

Who was elected to Theratechnologies (THTX) Board of Directors in 2025?

Eight directors were elected: Joseph Arena, Frank Holler, Paul Lévesque, Andrew Molson, Dawn Svoronos, Elina Tea, Dale Weil, and Jordan Zwick.

What was the highest approval rate for THTX board members in the 2025 election?

Joseph Arena received the highest approval rate with 84.03% of shareholders voting in favor.

What additional matters were approved at Theratechnologies' 2025 annual meeting?

Shareholders approved the appointment of KPMG LLP as auditors and an omnibus long-term incentive plan for directors, executive officers, and employees.